Expansion of all the diabetes treatments’ insurance benefits, solving doctors’ dilemmas

Although DPP-4 inhibitors, SGLT-2 inhibitors, basal insulin and GLP-1 analogues have different mechanisms, they are all used to cure diabetes.

These treatments, however, are practically included in the insurance benefit expansion. The insurance benefit standard of DPP-4 inhibitors was eased previously, SGLT-2 inhibitors, the new strong diabetes treatment, were also improved in the benefit now,...